
Top Stories 
Published On September 22, 2006
POLICY
Blood Feud
The testing of artificial blood has sparked controversy over individual rights.
The balance between individual rights and medical progress has sparked controversy over two trials under review by the Food and Drug Administration (FDA). Both studies are aimed at gauging the effectiveness of blood substitutes in helping trauma victims.
In ambulances and on battlefields, the use of real blood is virtually impossible because of short shelf life, refrigeration requirements and the need to cross-match types. What’s more, patients tend to be in no condition to provide informed consent. So one study, recently completed, operated under a waiver of consent (which the FDA may allow for research on acute, life-threatening conditions), as will the other if it’s approved by the FDA.
PolyHeme, developed by Northfield Laboratories of Evanston, Ill., was tested in ambulances and emergency rooms at 32 Level 1 trauma centers. In the ambulance tests, PolyHeme offered patients potential benefits because it carries tissue-saving oxygen (otherwise patients would typically receive saline, which only restores blood volume). But the research protocol also called for PolyHeme to be continued up to six units or 12 hours (whichever came first), long after patients reached the ER. This requirement allowed PolyHeme’s effectiveness to be directly compared to donor blood instead of saline.
Although Hemopure, the other substitute, would be tested only in ambulances, controversy over PolyHeme may be fueling resistance to the Hemopure trial, stalled since 2005 because of safety concerns. “PolyHeme has sensitized people to the waiver-of-consent issue,” says Guy Schein, a spokesperson for the U.S. Navy, which is helping fund the Hemopure study with its maker, Biopure Corp. in Cambridge, Mass.
Both PolyHeme and Hemopure have been linked to patient risks, including increased hypertension and other cardiac problems. Both manufacturers, however, contend that benefits outweigh risks.
In places where PolyHeme was tested, hospitals consulted with community members about risks and provided a procedure for opting out. But ethical concerns arose over whether these measures were an adequate substitute for traditional informed consent. In 1998, a nonconsent trial of a blood substitute from Baxter Healthcare was halted after yielding higher mortality rates. Still, Roger J. Lewis, a physician at the Harbor-UCLA Medical Center and chairman of the Data Safety Monitoring Board, an independent oversight body that recommended the halt, doesn’t think nonconsent trials are necessarily unethical: “If you take that position, you’re condemning all future patients to receive the same therapies we use today.”
Others don’t agree. “Is it ethical to substitute a known lifesaving intervention with an unproven one without consent?” asks Leonard Glantz, a lawyer and ethicist at the Boston University School of Public Health. (He served on a review board at the BU Medical Center that declined to participate in the PolyHeme trial.) “The answer is no, across the board.”
Dispatches

What Makes a Kid Clumsy? More research into coordination disorders shows why some children are more prone to trip, fumble and spill the milk.

Eyes in the Sky Satellite data can be used to assess the health impact of dust storms and the spread of mosquito-borne diseases. Additional applications could be on the horizon.

Could This One Change Help Curb the Opioid Crisis? To prescribe an effective bridge to addiction treatment, emergency physicians must get special training and receive a waiver. Making that process easier—or eliminating the requirement altogether—could make a big impact.

One Thing Leads to the Next Robert Lefkowitz is best known for revealing the mechanism behind hundreds of drugs in use today. But he thinks of himself as a storyteller first and has a new book out to make his case.

Podcast: The Research Year That Was Medical research labs have faced a difficult stretch of closed buildings and competing priorities. Yet they have also produced milestone discoveries—and not only on COVID-19.

The Shape of Us Two milestone discoveries in protein modeling promise to change the fundamentals of drug discovery.

Universal Flu Vaccines Move Forward In the shadow of coronavirus vaccine development, another vaccine was making solid progress.

Top Stories 

The Neuroscience of Giving Up
Why do some people react poorly, even catastrophically, in emergency situations?